Quantcast

Latest Orphan drug Stories

2014-02-14 23:21:13

MarketReportsOnline.com adds "US Orphan Drug Market Outlook 2018" report to its research store. Dallas, Texas (PRWEB) February 14, 2014 In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA...

2014-02-13 12:21:35

DUBLIN, Feb. 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kknn78/orphan_drugs_in ) has announced the addition of Just Pharma Reports's new report "Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a...

2014-02-07 08:22:40

NEW DELHI, February 7, 2014 /PRNewswire/ -- KuicK Research releases "Global Orphan Drug Market Outlook 2018" research report offering comprehensive insight on recent trends, regulatory development related to US orphan drug market, Europe orphan drug market & Asia orphan drug market. Report also gives insight on more than 600 orphan drugs in clinical pipeline and 231 marketed orphan drugs. Global Orphan Drug Market Report Findings: - Orphan...

2014-02-04 23:00:35

EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html). Orphan status brings additional momentum and acceleration to the...

2014-02-04 00:21:05

EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb. 4, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia. Vatiquinone is the International Nonproprietary Name (INN) for Edison's EPI-743. The INN is a unique international name issued by the World Health Organization. It is used to identify the active pharmacological...

2014-01-29 23:25:48

Keller brings strong niche brand experience to high science agency. Chicago, IL (PRWEB) January 29, 2014 Discovery USA, a high-science marketing and communications agency and part of Publicis Healthcare Communications Group (PHCG), announced the appointment of Kristin M. Keller as Executive Vice President, Client Engagement. In this role, Keller is responsible for expanding Discovery’s offerings, ensuring Discovery’s clients are connected to the full range of services and expertise...

2014-01-28 12:29:00

Annual Rare Disease Day event to benefit rare/orphan disease research CARLSBAD, Calif., Jan. 28, 2014 /PRNewswire/ -- Agility Clinical, Inc., a specialty consulting and contract research organization, and BIOCOM will host "Overcoming Challenges in Orphan Product Development", a special event in support of Rare Disease Day 2014 on February 27 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA. The event will feature speakers who are experts in orphan product...

2014-01-22 08:28:52

DURHAM, N.C., Jan. 22, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that the European Commission (EC) has granted orphan drug designation for SD-101 for the treatment of patients with Epidermolysis Bullosa (EB), a group of rare genetic skin diseases. This decision follows a positive opinion adopted by the Committee for Orphan Medicinal Products (COMP), recommending such designation. Epidermolysis Bullosa is a rare genetic connective tissue condition that, in all of its...

2014-01-13 08:26:33

CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug Designation for ISIS-APOCIII(Rx) for the treatment of patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease characterized by extremely high triglyceride levels that affects an estimated 3,000 to 5,000 patients worldwide. ISIS-APOCIII(Rx )is a wholly...

2014-01-05 23:03:02

RadioMedix, Inc. is proud to announce that the company has received approval of “Orphan Drug Designation” for 68Ga-DOTATATE (GalioMedix ™) as a diagnostic agent for the management of patients with neuroendocrine tumors (NETs) by U.S Food and Drug Administration (FDA). Houston, TX (PRWEB) January 05, 2014 RadioMedix, Inc. is proud to announce that the company has received approval of “Orphan Drug Designation” for 68Ga-DOTATATE (GalioMedix ™) as a diagnostic agent for the...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related